Viking Therapeutics Company
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.
Technology:
Cancer
Industry:
P4 Medicine
Headquarters:
San Diego, California, United States
Zip:
11-50
Founded Date:
2012-01-01
Employees Number:
11-50
Funding Status:
IPO
Acquisitions Number:
2
Investors Number:
181500000
Total Funding:
$1M to $10M
Estimated Revenue:
2015-04-13
Last Funding Date:
Post-IPO Equity
Last Funding Type:
info@vikingtherapeutics.com
Register and Claim Ownership